Dry Age-related Macular Degeneration
Conditions
Brief summary
The aim of this clinical trial is to evaluate the effect of low doses of antiplatelet medications (aspirin 81 mg/day or clopidogrel 75 mg/day) with or without a combination of antioxidants (N-acetylcysteine 600 mg/day) in a dry AMD patient with large drusen. Participants will divided in to three groups. * Participants who were already taking low dose antiplatelet medications. * Participants who take the antiplatelet drug mentioned above in addition to the antioxidant prescribed by the investigator * Participants does not use any medications.
Interventions
Patients take aspirin 81 mg per day.
DRUGClopidogrel
Patients take clopidogrel 75 mg per day.
DRUGN-acetylcysteine
Patients are given N-acetylcysteine 600 mg per day.
Sponsors
Navamindradhiraj University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Intervention model description
1. Aspirin 81 mg/d or Clopidogrel 75 mg/d 2. Aspirin 81 mg/d or Clopidogrel 75 mg/d with N-acetylcysteine 600 mg/d 3. No medication
Eligibility
Sex/Gender
ALL
Age
50 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Dry AMD with at least 1 large drusen. According to the AREDS study, large drusen have a size of more than 125 micron. * Patients can evaluate SD-OCT (Spectral domain optical coherence tomography), OCT angiography, and best-corrected visual acuity. * Age range: 50-85 years * Patients who have previously used antiplatelet drugs.
Exclusion criteria
* Patient with advanced AMD, such as geographic atrophy, neovascular complications (choroidal neovascularization) * Patient with additional retinal diseases that affect visual acuity, e.g., retinal detachment, diabetic macular edema. * Patient with a history of intravitreal anti-VEGF injection or macular laser. * Patient using SSRIs, SNRIs, azole, NSAIDs, dual antiplatelet, anticoagulant medications.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Drusen volume analysis | 1 year | To assess AMD progression in patient with large drusen, drusen volume was measured and analyzed in each patient group by OCT scan |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Best-corrected visual acuity change | 1 year | To evaluate Best-corrected visual acuity in each patient group by ETDRS chart |
| Rate of disease progression | 1 year | To evaluate disease progression to geographic atrophy or neovascular AMD by OCT scan and fundus photo |
| Side effects of medications intake | 1 year | To evaluate the safety of the medication used by questionnaire |
Countries
Thailand
Contacts
Primary ContactYolradee Winuntamalakul
Outcome results
None listed